News | November 03, 2010

FDA Approves LAA Closure Device Study


November 3, 2010 – The first patient has been enrolled into a study comparing a left atrial appendage (LAA) closure device to warfarin therapy in those with atrial fibrillation. The PREVAIL study will look at Atritech’s Watchman LAA closure device.

Central Baptist Hospital in Lexington, Ky., enrolled the first patient.

"We are pleased to have enrolled the first patient in the PREVAIL study,” said Gery Tomassoni, M.D., director of research at Central Baptist Hospital. “Our experience in the PROTECT AF study was very positive. We look forward to being a major enrolling center in this study and being able to offer an alternative to long term anticoagulation therapy to our patients."

The Watchman device is designed to keep harmful sized blood clots from entering a patient's blood stream, potentially causing a stroke. Patients with atrial fibrillation are at a greater risk of having a stroke due to the formation of clots in an area of the heart called the left atrial appendage (LAA). Atrial fibrillation occurs when the upper chambers of the heart beat too rapidly. Typically these patients require blood-thinning medications such as warfarin to prevent these clots from forming in the heart.

The PROTECT AF clinical study compared the Watchman to the current standard of care, warfarin, in patients with non-valvular atrial fibrillation. The device received Circulatory Panel Approval in the United States in April 2009, but the U.S. Food and Drug Administration (FDA) requested a smaller confirmatory study be conducted before granting full approval.

The Watchman is commercially available in Europe and other major areas outside of the United States.

For more information: http://www.atritech.net


Related Content

News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
Subscribe Now